Management of Supratherapeutic INR with Bleeding in Mechanical Mitral Valve Patients

Immediate Assessment and Stabilization

The American College of Cardiology recommends immediately holding warfarin, administering intravenous vitamin K (1-2 mg by slow IV infusion), and giving fresh frozen plasma or prothrombin complex concentrate to rapidly reverse anticoagulation while simultaneously investigating and treating the source of bleeding in patients with mechanical mitral valves and supratherapeutic INR 1, 2
The American Heart Association suggests checking current INR immediately and assessing for active bleeding (hematemesis, melena, hematuria, intracranial hemorrhage, or other major bleeding sites) in patients with mechanical mitral valves and supratherapeutic INR 2
Obtaining a complete blood count to quantify the hemoglobin drop and assess ongoing blood loss is recommended for patients with mechanical mitral valves and supratherapeutic INR 3

The American College of Cardiology recommends administering intravenous vitamin K 1-2 mg by slow IV infusion (NOT high-dose 5-10 mg) to reverse anticoagulation in patients with mechanical mitral valves and supratherapeutic INR 1, 2
Giving fresh frozen plasma OR prothrombin complex concentrate for immediate clotting factor replacement is recommended for patients with mechanical mitral valves and supratherapeutic INR 1, 2

The American College of Cardiology suggests that mechanical mitral valves are high-risk for thrombosis, with a target INR of 2.5-3.5 (higher than aortic valves) 1, 4
Initiating bridging with intravenous unfractionated heparin (NOT subcutaneous LMWH initially) is recommended once bleeding is controlled and hemoglobin stabilizes in patients with mechanical mitral valves and supratherapeutic INR 1, 2

The American College of Cardiology recommends restarting warfarin at a lower dose than previous maintenance (typically reduce by 10-20% of weekly dose) once bleeding is fully controlled in patients with mechanical mitral valves and supatherapeutic INR 3
Monitoring INR daily initially, then every 2-3 days until stable in therapeutic range of 2.5-3.5 is recommended for patients with mechanical mitral valves and supratherapeutic INR 1, 4

The American Geriatrics Society suggests reviewing all medications, including over-the-counter drugs and supplements, to identify potential causes of supratherapeutic INR with bleeding in patients with mechanical mitral valves 3, 5
Assessing liver and thyroid function is recommended to identify potential causes of supratherapeutic INR with bleeding in patients with mechanical mitral valves 3, 5

The American College of Cardiology warns against giving high-dose vitamin K (>2.5 mg) routinely, as this creates warfarin resistance lasting weeks and puts the patient at thrombotic risk 1, 2
Delaying heparin bridging excessively is discouraged, as mechanical mitral valves can thrombose within days of subtherapeutic anticoagulation 1, 2, 4

The American Geriatrics Society recommends checking INR daily during the acute phase and reversal period in patients with mechanical mitral valves and supratherapeutic INR 3, 5
Monitoring activated partial thromboplastin time (aPTT) when on heparin bridge is recommended for patients with mechanical mitral valves and supratherapeutic INR 1, 2

The American College of Cardiology recommends therapeutic doses of intravenous UFH when INR falls below 2.0 in patients with mechanical valve replacement, continuing until INR is therapeutic again 6
Mechanical prosthetic valves, particularly in the mitral position, carry extremely high thrombotic risk and can develop valve thrombosis within days of subtherapeutic anticoagulation 6

The dose reduction of 10-15% from the previous maintenance dose accounts for the fact that the patient became supratherapeutic on their previous dose, indicating excessive anticoagulation at that dose 7
The American College of Cardiology and European Heart Society guidelines support reducing the weekly warfarin dose by 10-15% from the previous maintenance dose after a supratherapeutic INR episode 7

A 10-15% weekly dose reduction is the standard approach after supratherapeutic INR episodes, as simply restarting at the same dose that caused supratherapeutic INR will likely result in recurrent elevation 7
The patient's INR was supratherapeutic on their previous dose, demonstrating this dose produces excessive anticoagulation 7

Continue IV heparin until INR reaches therapeutic range (2.5-3.5 for prosthetic valve) on two consecutive measurements, as recommended by the American College of Cardiology 6
Once INR is therapeutic, continue warfarin and heparin together for at least 24 hours with therapeutic INR before discontinuing heparin, as per the American Heart Association guidelines 6

Mitral position mechanical valves require INR 2.5-3.5, as recommended by the American College of Cardiology 6
Aortic position bileaflet valves target INR 2.0-3.0, according to the European Society of Cardiology guidelines 6

Prosthetic heart valves represent the highest thrombotic risk category requiring most reliable anticoagulation, making IV heparin the preferred choice over LMWH, as stated by the American College of Cardiology 6
The European Heart Society recommends continuing heparin bridge until INR is therapeutic for at least 24 hours, preferably with two consecutive therapeutic measurements 6